Investment Boost for POC4TRIAGE Partner TrianecT Accelerates Stroke Innovation
When every minute counts, technology can mean the difference between recovery and lifelong disability. That’s the driving force behind StrokePointer™, a portable diagnostic device developed by TrianecT. Now, with a fresh €1.35 million investment, it’s one step closer to reaching patients across Europe.
The funding round, led by XO Ventures and CbusineZ, will support the commercial development and market launch of StrokePointer™. The device assesses the severity of a stroke in the back of an ambulance by measuring electrical brain activity. When a severe stroke (often large vessel occlusion) is detected, paramedics can route patients directly to specialized stroke centers, which saves critical time for the patient.
For the POC4TRIAGE consortium, of which TrianecT is a key member, this milestone is more than company news, it’s a validation of the project’s mission to bring advanced point-of-care diagnostics to emergency settings. “Thanks to this investment—and the involvement of our new partners—we can accelerate the translation of our technology from scientific breakthrough to frontline tool,” said Wouter Potters, CEO and co-founder of TrianecT.
We congratulate our partner on this major step forward and look forward to continuing our collaboration as we work together to improve emergency care across Europe.
Press release from TrianecT
